ABL Diagnostics H1FY26 Results: Revenue up 90%, net profit jumps 343%

ScanX News ABL Diagnostics H1FY26 Results: Revenue up 90%, net profit jumps 343% 1 min read | Published on 08 Sept 2026, 10:18 PM | Updated on 08 Sept 2026, 10:18 PM Reviewed by Add as a preferred source on Google *this image is generated using AI for illustrative purposes only. ABL Diagnostics (Euronext: ABLD) reported a 90.0% revenue surge in the first half of FY26, driven by the ramp-up of its UltraGene range and new distribution activities. The molecular diagnostics firm posted revenue of €5.415 million for the six months ended June 30, 2026, compared to €2.849 million in the same period last year. This performance reflects the integration of Vela Diagnostics and CDL Pharma distribution services alongside historical genotyping activities. Financial Performance Operating profitability expanded significantly as fixed costs were absorbed by higher activity levels. EBITDA rose 346.5% year-on-year to €1.315 million, with the margin widening from 10.3% to 24.3%. Operating income (EBIT) turned positive at €1.115 million, reversing an operating loss of €0.066 million recorded in H1FY25. Net income climbed 343.4% to €1.280 million. This figure already exceeds the company's full-year FY25 net income of €0.987 million by 29.7%, highlighting accelerated profit generation despite revenue reaching only 77.9% of the previous year's total. Metric H1FY26 H1FY25 Change Revenue €5.415 million €2.849 million +90.0% EBITDA €1.315 million €0.295 million +346.5% EBITDA Margin 24.3% 10.3% +14.0 pts Net Income €1.280 million €0.289 million +343.4% What the Numbers Show The divergence between revenue growth and cash position warrants attention. While revenue nearly doubled, free cash declined 6.4% to €853 million from €912 million in the prior period. Available cash on the balance sheet fell 35.2% to €853k as of June 30, 2026, down from €1.316 million at year-end 2025. This contraction aligns with working capital movements and investments made during the period, including the transfer of €255k in assets to support the takeover of Texcell France operations. Strategic Developments ABL Diagnostics integrated the assets of Texcell France following a Commercial Court approval in July 2026, adding 29 employees to its workforce. The company maintains its FY26 revenue target of €12.265 million, having achieved 44.2% of this goal in the first half. The roadmap relies on continued growth from UltraGene, HIV business units, and international trade network expansion. Research and development expenses eligible for tax credits totaled €1.150 million, generating an estimated CIR/CII benefit of €345k. The Board approved these half-year financial statements on September 8, 2026, subject to limited review by the statutory auditor. How will the integration of Texcell France operations impact ABL Diagnostics' operational efficiency and cost structure in the second half of FY26? fuzz it What specific strategies is the company employing to reverse the decline in free cash flow despite significant revenue and EBITDA growth? fuzz it To what extent will the expansion of the international trade network contribute to achieving the remaining 55.8% of the €12.265 million FY26 revenue target? fuzz it ScanX News ABL Diagnostics H1FY26 Results: Revenue up 90%, net profit jumps 343% 1 min read | Published on 27 Aug 2026, 09:58 PM | Updated on 27 Aug 2026, 09:58 PM Reviewed by Anirudha B ScanX News Team Add as a preferred source on Google *this image is generated using AI for illustrative purposes only. ABL Diagnostics (Euronext: ABLD) disclosed its share capital and voting rights structure as of August 12, 2026, in a regulatory filing. The Paris-listed molecular biology diagnostics firm reported a total share capital comprising 16,114,656 shares. The company's filing, mandated by Articles L. 233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation, provides a breakdown of voting power attached to these shares. Share Capital and Voting Rights As per the disclosure, the total number of shares constituting the share capital stands at 16,114,656. The associated voting rights are detailed below: Metric Count Total Shares 16,114,656 Theoretical Voting Rights 30,501,420 Exercisable Voting Rights 30,471,564 Theoretical voting rights include all shares to which voting rights are attached, even if suspended or deprived. Exercisable voting rights represent those currently active for shareholder decisions. Double Voting Rights Mechanism The disparity between the number of shares and theoretical voting rights stems from a double voting right mechanism. Resolutions adopted on March 23, 2022, grant double voting rights to all fully paid-up shares registered in the name of the same shareholder for at least two years. This provision has been effective since March 23, 2022. Business Overview Headquartered in Woippy, France, ABL Diagnostics specializes in innovative molecular biology tests. Its core product portfolio includes: Molecular polymerase chain reaction (PCR) detection via UltraGene. Genotyping by DNA sequencing through DeepChek. The company markets its solutions globally through an internal sales team and exclusive distributors. Key customers include academic clinical pathology laboratories, private reference labs, and researchers. Recent strategic moves include the acquisition of TEXCELL's operations, expanding ABL Diagnostics' activities in virology, biosafety testing, and biopharmaceutical development support. Additionally, since the second half of 2025, the firm has marketed products from its sister company CDL Pharma under an intra-group strategy agreement. How might the double voting rights structure impact potential takeover defenses or future M&A activity for ABL Diagnostics? fuzz it What is the projected revenue contribution from the newly acquired TEXCELL operations in virology and biosafety testing for the upcoming fiscal year? fuzz it Could the intra-group strategy with CDL Pharma lead to further consolidation within the ABL group or cross-selling opportunities in new therapeutic areas? fuzz it view all